Fundraising FoxRA Capital — 2015 Investments
8 investments dated 2015 · listed companies and verified rows first · show all
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+15 more
Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.
BiotechHealthtechLongevitySingapore, US
Takeshi Wada(Director)inGregory L. Verdine(Director)Paul B. Bolno, M.D.(Executive Officer, Director)inPaul Bolno, MD, MBA(President and Chief Executive Officer, Wave Life Sciences)
BoardKen Takanashi(Director)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsForesite CapitalAescap Life Sciences
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in
BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)
Co-investors3E Bioventures CapitalBain Capital Life SciencesNextech InvestCobro Ventures
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsAisling CapitalCanaan PartnersJJDCJohnson & Johnson Innovation – JJDCLilly VenturesStarfish Ventures
UCB is a global biopharmaceutical company that develops medicines and treatment-support services for people living with neurological and autoimmune conditions, including rare diseases such as epilepsy.
BiotechHealthtechCambridge, US
Douglas A. Treco(Executive Officer, Director)Kerry Black(Executive Officer)in
BoardEdward Mathers(Director)Rajeev Shah(Director)inPeter Bisgaard(Director)Jason Lettman(Director)
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Morgenthaler
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.